PDCD1 and head and neck squamous cell carcinoma: In addition to cytotoxic chemotherapeutic agents, epidermal growth factor receptor and tyrosine kinase inhibitors, two immune checkpoint inhibitors targeting programmed cell death protein 1 (pembrolizumab and nivolumab), are currently used for patients with recurrent or metastatic HNSCC, but their clinical efficacy is still limited [67].